PACTR202102892966266Not yet recruitingPhase 1
Enhancing brain development by early iron supplementation of African infants: An enabling pilot study
Medical Research Council at London School of Hygiene and Tropical Medicine0 sites100 target enrollmentStarted: December 7, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 0 Month(s) to 23 Month(s) (—)
- Sex
- All
Inclusion Criteria
- •Infants (male or female) at 6 weeks of age
- •Breast fed infants (with plans to continue breastfeeding through 6 months of age).
- •Parent/guardian with participant reside in study site area and are able and willing to adhere to all protocol visits and procedures (willingness to stay in the study area for the 14 weeks of supplementation).
- •Healthy with no current illness and no chronic health problems.
- •Signed or fingerprinted informed consent obtained from participants parent/guardian.
Exclusion Criteria
- •Low birthweight babies (i.e. less than 2.5kg at birth) or babies born prematurely (i.e. less than 37 weeks) will NOT be excluded.
- •Formula fed infants or those planning to terminate exclusive breast feeding before 6months of age.
- •Acute illness (once acute illness is resolved, if appropriate, as per investigator assessment, participant may be re-revaluated for eligibility).
- •Fever (for eligibility purpose defined as a body temperature greater than 37.5°C or mother report of fever) within 3 days prior to study initiation (once fever/acute illness is resolved, if appropriate, as per investigator assessment, participant may be re-revaluated for eligibility).
- •Administration of any investigational drug within 30 days prior to study initiation or planned administration during the study period.
- •Unwilling to avoid (their child to avoid) the ingestion of supplements or herbal/other traditional medications during the study period.
- •Any history of or evidence for chronic clinically significant (as per investigator assessment) disorder or disease (including, but not limited to, immunodeficiency, autoimmunity, congenital abnormality, bleeding disorder, and pulmonary, cardiovascular, metabolic, neurologic, renal, or hepatic disease).
- •Any history of human immunodeficiency virus, chronic hepatitis B or chronic hepatitis C infections.
- •History of meningitis, seizures, Guillain-Barre´ syndrome, or other neurological disorders.
- •Any condition that in the opinion of the investigator might compromise the safety or well- being of the participant or compromise adherence to protocol procedures.
Investigators
Similar Trials
Completed
Not Applicable
Neurodevelopment After Early Iron SupplementationIron DeficiencyAnemia of PrematurityNeurodevelopmental DelayNCT00457990University of Ulm204
Not yet recruiting
Not Applicable
Iron supplements in small babies during first year of lifeCTRI/2017/02/007958ICMR200
Completed
Phase 4
Iron Supplementation of Marginally Low Birth Weight InfantsIron-DeficiencyChild Behavior DisordersCognitive ManifestationsAnemiaNCT00558454Umeå University380
Completed
Phase 3
Iron Supplementation and Neurodevelopmental Outcome in ELGANsIron-deficiencyNCT04691843Ann & Robert H Lurie Children's Hospital of Chicago51
Not yet recruiting
Phase 3
Effects of iron supplementation on neurocognitive developmentIRCT20210205050253N1Sheikh Zayed Medical College / Hospital Rahim Yar Khan204